New triple therapy aims to protect kidneys in diabetes patients
NCT ID NCT07537088
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding a weekly injection called dulaglutide to two standard pills (SGLT-2 inhibitors and finerenone) can better protect the kidneys of Chinese adults with type 2 diabetes and mild-to-moderate chronic kidney disease. About 468 participants will be randomly assigned to either continue their current two-drug regimen or add dulaglutide for 26 weeks. The main goal is to see if the triple therapy reduces protein in the urine, a key sign of kidney damage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dulaglutide (a once-weekly injection for diabetes) added to SGLT-2 inhibitors and finerenone (both pills)
What this could lead to
If it works, this could point toward a better way to slow kidney damage in people with type 2 diabetes and chronic kidney disease.
What could go wrong
This is a phase 4 trial with 468 participants over 26 weeks, so results may not apply to all patients. Adding dulaglutide may increase side effects like nausea or diarrhea without clear kidney benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T2DM (TYPE 2 DIABETES MELLITUS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••